Progesterone for prEventing Preterm births in women with PlacEnta pRevia (PEPPER-trial)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507763-18-01

Enrollment

142

Registered

2024-02-16

Start date

2024-05-21

Completion date

Unknown

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta previa, preterm birth

Brief summary

Number of PTB before 37 weeks of gestation

Detailed description

1. sPTB/iPTB <37wks, 2. PTB >24wks, 3. Total PTB, sPTB, iPTB <28/32/34wks, 4. Mean gestational age, 5. Incidence of <10th/3rd percentile birthweight, 6. Umbilical cord blood pH (arterial/venous), 7. Apgar <7 at 5 mins, 8. NICU admissions (>24 hrs, hrs in NICU), 9. Components of composite outcome, 10. Planned/unplanned CS, 11. Admission for antenatal blood loss (incidence), 12. Threatened preterm birth (incidence).

Interventions

DRUGPROGESTERONE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of PTB before 37 weeks of gestation	—

Secondary

Measure	Time frame
1. sPTB/iPTB <37wks, 2. PTB >24wks, 3. Total PTB, sPTB, iPTB <28/32/34wks, 4. Mean gestational age, 5. Incidence of <10th/3rd percentile birthweight, 6. Umbilical cord blood pH (arterial/venous), 7. Apgar <7 at 5 mins, 8. NICU admissions (>24 hrs, hrs in NICU), 9. Components of composite outcome, 10. Planned/unplanned CS, 11. Admission for antenatal blood loss (incidence), 12. Threatened preterm birth (incidence).	—

Measure

Time frame

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026